Halberd Corp
OTC:HALB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Halberd Corp
Change in Working Capital
Halberd Corp
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Halberd Corp
OTC:HALB
|
Change in Working Capital
-$98.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$10B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Change in Working Capital
-$444.8m
|
CAGR 3-Years
-132%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Change in Working Capital
$86.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Change in Working Capital
-$106.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Change in Working Capital
$233m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
Halberd Corp
Glance View
Halberd Corp. is a development stage company, researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. The company is headquartered in Jackson Center, Pennsylvania. The company went IPO on 2009-06-12. The firm is a research-based company that intends to discover and develop medical treatments for a range of diseases. The firm's extracorporeal treatment is applicable for hard-to-cure blood-borne and neurologic diseases, such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. The company is also developing treatment for coronavirus disease of 2019 (Covid-19), obesity, such as high blood pressure, diabetes, heart disease, stroke, and cancer.
See Also
What is Halberd Corp's Change in Working Capital?
Change in Working Capital
-98.2k
USD
Based on the financial report for Jul 31, 2012, Halberd Corp's Change in Working Capital amounts to -98.2k USD.
What is Halberd Corp's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
43%
Over the last year, the Change in Working Capital growth was 43%.
